CGEM Projected Dividend Yield
Cullinan Oncology Inc ( NASDAQ : CGEM )Cullinan Oncology is a biopharmaceutical company. Zipalertinib (CLN-081/TAS6417) which Co. is co-developing with an affiliate of Taiho Pharmaceutical, Co. Ltd (Taiho), is an orally bioavailable small-molecule, irreversible epidermal growth factor receptor (EGFR) inhibitor that is designed to selectively target cells expressing EGFR exon 20 insertion (EGFRex20ins) mutations with relative sparing of cells expressing wild-type EGFR. In addition to zipalertinib, Co.'s portfolio includes four other clinical-stage product candidates and one product candidate that is pending the U.S. Food and Drug Administration clearance for its investigational new drug application. 20 YEAR PERFORMANCE RESULTS |
CGEM Dividend History Detail CGEM Dividend News CGEM Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |